193 related articles for article (PubMed ID: 35080453)
1. Lung-RADS Category 3 and 4 Nodules on Lung Cancer Screening in Clinical Practice.
Mendoza DP; Petranovic M; Som A; Wu MY; Park EY; Zhang EW; Archer JM; McDermott S; Khandekar M; Lanuti M; Gainor JF; Lennes IT; Shepard JO; Digumarthy SR
AJR Am J Roentgenol; 2022 Jul; 219(1):55-65. PubMed ID: 35080453
[No Abstract] [Full Text] [Related]
2. Characterizing Lung-RADS category 4 lesions in a university lung cancer screening program.
Kocher Wulfeck M; Plesner S; Herndon JE; Christensen JD; Patz EF
Lung Cancer; 2023 Dec; 186():107420. PubMed ID: 37956610
[TBL] [Abstract][Full Text] [Related]
3. Malignant Nodules Detected on Lung Cancer Screening CT: Yield of Short-Term Follow-Up CT in Showing Nodule Growth.
Byrne SC; Hammer MM
AJR Am J Roentgenol; 2022 Nov; 219(5):735-741. PubMed ID: 35674352
[No Abstract] [Full Text] [Related]
4. Real-World Lung Cancer CT Screening Performance, Smoking Behavior, and Adherence to Recommendations: Lung-RADS Category and Smoking Status Predict Adherence.
Barbosa EJM; Yang R; Hershman M
AJR Am J Roentgenol; 2021 Apr; 216(4):919-926. PubMed ID: 32755178
[No Abstract] [Full Text] [Related]
5. Cancer Risk in Nodules Detected at Follow-Up Lung Cancer Screening CT.
Hammer MM; Byrne SC
AJR Am J Roentgenol; 2022 Apr; 218(4):634-641. PubMed ID: 34755524
[No Abstract] [Full Text] [Related]
6. Rate of benign nodule resection in a lung cancer screening program.
El Alam R; Byrne SC; Hammer MM
Clin Imaging; 2023 Dec; 104():109984. PubMed ID: 37832324
[TBL] [Abstract][Full Text] [Related]
7. Receipt of Recommended Follow-up Care After a Positive Lung Cancer Screening Examination.
Rivera MP; Durham DD; Long JM; Perera P; Lane L; Lamb D; Metwally E; Henderson LM
JAMA Netw Open; 2022 Nov; 5(11):e2240403. PubMed ID: 36326760
[TBL] [Abstract][Full Text] [Related]
8. Strategies for Reducing False-Positive Screening Results for Intermediate-Size Nodules Evaluated Using Lung-RADS: A Secondary Analysis of National Lung Screening Trial Data.
Hammer MM; Hunsaker AR
AJR Am J Roentgenol; 2022 Sep; 219(3):397-405. PubMed ID: 35319912
[No Abstract] [Full Text] [Related]
9. Lung-RADS Version 1.0 versus Lung-RADS Version 1.1: Comparison of Categories Using Nodules from the National Lung Screening Trial.
Kastner J; Hossain R; Jeudy J; Dako F; Mehta V; Dalal S; Dharaiya E; White C
Radiology; 2021 Jul; 300(1):199-206. PubMed ID: 33944631
[TBL] [Abstract][Full Text] [Related]
10. Malignancy estimation of Lung-RADS criteria for subsolid nodules on CT: accuracy of low and high risk spectrum when using NLST nodules.
Chung K; Jacobs C; Scholten ET; Mets OM; Dekker I; Prokop M; van Ginneken B; Schaefer-Prokop CM
Eur Radiol; 2017 Nov; 27(11):4672-4679. PubMed ID: 28439653
[TBL] [Abstract][Full Text] [Related]
11. Lung-RADS Category 4X: Does It Improve Prediction of Malignancy in Subsolid Nodules?
Chung K; Jacobs C; Scholten ET; Goo JM; Prosch H; Sverzellati N; Ciompi F; Mets OM; Gerke PK; Prokop M; van Ginneken B; Schaefer-Prokop CM
Radiology; 2017 Jul; 284(1):264-271. PubMed ID: 28339311
[TBL] [Abstract][Full Text] [Related]
12. A Comparison of the PanCan Model and Lung-RADS to Assess Cancer Probability Among People With Screening-Detected, Solid Lung Nodules.
Sundaram V; Gould MK; Nair VS
Chest; 2021 Mar; 159(3):1273-1282. PubMed ID: 33393476
[TBL] [Abstract][Full Text] [Related]
13. Delays in Recommended Follow-Up after Positive Findings in Lung Cancer Screening.
Ahmed A; Hippe DS; Snidarich M; Crothers K; Triplette M
Ann Am Thorac Soc; 2023 Aug; 20(8):1175-1181. PubMed ID: 36973008
[No Abstract] [Full Text] [Related]
14. Improved Interobserver Agreement on Lung-RADS Classification of Solid Nodules Using Semiautomated CT Volumetry.
Gierada DS; Rydzak CE; Zei M; Rhea L
Radiology; 2020 Dec; 297(3):675-684. PubMed ID: 32930652
[TBL] [Abstract][Full Text] [Related]
15. Factors Associated With Nonadherence to Lung Cancer Screening Across Multiple Screening Time Points.
Lin Y; Liang LJ; Ding R; Prosper AE; Aberle DR; Hsu W
JAMA Netw Open; 2023 May; 6(5):e2315250. PubMed ID: 37227725
[TBL] [Abstract][Full Text] [Related]
16. Cancer Risk in Subsolid Nodules in the National Lung Screening Trial.
Hammer MM; Palazzo LL; Kong CY; Hunsaker AR
Radiology; 2019 Nov; 293(2):441-448. PubMed ID: 31526256
[TBL] [Abstract][Full Text] [Related]
17. Insights for Management of Ground-Glass Opacities From the National Lung Screening Trial.
Robbins HA; Katki HA; Cheung LC; Landy R; Berg CD
J Thorac Oncol; 2019 Sep; 14(9):1662-1665. PubMed ID: 31125735
[TBL] [Abstract][Full Text] [Related]
18. Management and Outcomes of Suspected Infectious and Inflammatory Lung Abnormalities Identified on Lung Cancer Screening CT.
Mendoza DP; Chintanapakdee W; Zhang EW; Gilman MD; Lennes IT; Frank AJ; Shepard JO; Digumarthy SR
AJR Am J Roentgenol; 2021 Nov; 217(5):1083-1092. PubMed ID: 33377416
[No Abstract] [Full Text] [Related]
19. Lung cancer screening with MRI: Evaluation of MRI for lung cancer screening by comparison of LDCT- and MRI-derived Lung-RADS categories in the first two screening rounds.
Meier-Schroers M; Homsi R; Gieseke J; Schild HH; Thomas D
Eur Radiol; 2019 Feb; 29(2):898-905. PubMed ID: 29992387
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Lung-RADS Version 1.1 and Lung-RADS Version 2022 in Classifying Airway Nodules Detected at Lung Cancer Screening CT.
DeSimone AK; Byrne SC; Hammer MM
Radiol Cardiothorac Imaging; 2024 Feb; 6(1):e230149. PubMed ID: 38300115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
